Alteogen Inc.
196170
주식 순위
#1912
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
주가
$159.04
시가총액
$11.07B
변동 (1일)
-2.95%
변동 (1년)
-48.94%
국가
KR
거래 Alteogen Inc. (196170)
카테고리
Healthcare
Alteogen Inc. (196170)의 배당 이력
Alteogen Inc. (주식 심볼: 196170)은 총 1회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): $371.00
배당 수익률 (TTM): 0.0018
모든 배당금의 합계 (주식 분할 반영): $371.00
배당 수익률 (TTM): 0.0018
Alteogen Inc. (196170)의 2025부터 2026까지 배당 지급 내역
연간 배당 지급
| 연도 | 배당금 (주식 분할 조정됨) | 변화 |
|---|---|---|
| 2026 (TTM) | $371.00 | 0.00% |
| 2025 | $371.00 | 0.00% |
모든 배당 지급 목록
| 연도 | 배당금 | 변화 |
|---|---|---|
| 2026 (TTM) | $371.00 | 0.00% |
| 2025 | $371.00 | 0.00% |
유사 기업 또는 경쟁사의 배당 지급
| 회사 | 배당 지급 횟수 | 국가 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
